{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:04:57Z","timestamp":1792807497863,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26388-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:58:58Z","timestamp":1762516738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic significance of Claudin18.2 expression in patients with gastric cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuichiro","family":"Miki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Bito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kasashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunari","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsune","family":"Shibutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Toyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"26388_CR1","doi-asserted-by":"publisher","first-page":"11542","DOI":"10.1038\/s41598-022-15839-7","volume":"12","author":"Y Song","year":"2022","unstructured":"Song, Y., Liu, X., Cheng, W., Li, H. & Zhang, D. The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019. Sci. Rep. 12, 11542 (2022).","journal-title":"Sci. Rep."},{"key":"26388_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"26388_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/den.12518","volume":"28","author":"H Ono","year":"2016","unstructured":"Ono, H. et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig. Endosc. 28, 3\u201315 (2016).","journal-title":"Dig. Endosc."},{"key":"26388_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamasurg.2023.0096","volume":"158","author":"T Etoh","year":"2023","unstructured":"Etoh, T. et al. Five-Year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: The JLSSG0901 randomized clinical trial. JAMA Surg. 158, 445\u2013454 (2023).","journal-title":"JAMA Surg."},{"key":"26388_CR5","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"26388_CR6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"26388_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang, Y.-K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234\u2013247 (2022).","journal-title":"Lancet Oncol."},{"key":"26388_CR8","first-page":"393","volume":"8","author":"O Jarvi","year":"1952","unstructured":"Jarvi, O. & Lauren, P. On the pathogenesis of gastric cancer. Acta - Unio Int. Contra Cancrum 8, 393\u2013394 (1952).","journal-title":"Acta - Unio Int. Contra Cancrum"},{"key":"26388_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s10120-014-0400-0","volume":"18","author":"CN Chen","year":"2015","unstructured":"Chen, C. N. et al. Connective tissue growth factor inhibits gastric cancer peritoneal metastasis by blocking integrin alpha3beta1-dependent adhesion. Gastric Cancer: Official J. Int. Gastric Cancer Assoc. Japanese Gastric Cancer Assoc. 18, 504\u2013515 (2015).","journal-title":"Gastric Cancer: Official J. Int. Gastric Cancer Assoc. Japanese Gastric Cancer Assoc."},{"key":"26388_CR10","unstructured":"TNM-Classification of Malignant Tumours. 7th edn (Wiley-Blackwell, 2009)."},{"key":"26388_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"key":"26388_CR12","unstructured":"Team, R. C. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"26388_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","volume":"12","author":"KH Jun","year":"2014","unstructured":"Jun, K. H., Kim, J. H., Jung, J. H., Choi, H. J. & Chin, H. M. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int. J. Surg. 12, 156\u2013162 (2014).","journal-title":"Int. J. Surg."},{"key":"26388_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","volume":"475","author":"M Dottermusch","year":"2019","unstructured":"Dottermusch, M., Kruger, S., Behrens, H. M., Halske, C. & Rocken, C. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch. 475, 563\u2013571 (2019).","journal-title":"Virchows Arch."},{"key":"26388_CR15","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","volume":"39","author":"JH Baek","year":"2019","unstructured":"Baek, J. H. et al. Clinical implications of Claudin18.2 expression in patients with gastric cancer. Anticancer Res. 39, 6973\u20136979 (2019).","journal-title":"Anticancer Res."},{"key":"26388_CR16","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.21037\/jgo-20-344","volume":"11","author":"B Xu","year":"2020","unstructured":"Xu, B. et al. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC). J. Gastrointest. Oncol. 11, 1431\u20131439 (2020).","journal-title":"J. Gastrointest. Oncol."},{"key":"26388_CR17","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.21037\/tcr-19-1876","volume":"9","author":"JY Hong","year":"2020","unstructured":"Hong, J. Y. et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl. Cancer Res. 9, 3367\u20133374 (2020).","journal-title":"Transl. Cancer Res."},{"key":"26388_CR18","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold, A. et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin. Transl. Oncol. 22, 2357\u20132363 (2020).","journal-title":"Clin. Transl. Oncol."},{"key":"26388_CR19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.21037\/jgo-20-463","volume":"11","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Correlation between Claudin-18 expression and clinicopathological features and prognosis in patients with gastric cancer. J. Gastrointest. Oncol. 11, 1253\u20131260 (2020).","journal-title":"J. Gastrointest. Oncol."},{"key":"26388_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5230\/jgc.2020.20.e33","volume":"20","author":"SR Kim","year":"2020","unstructured":"Kim, S. R. et al. Clinical significance of CLDN18.2 expression in metastatic diffuse-type gastric Cancer. J. Gastric Cancer 20, 408\u2013420 (2020).","journal-title":"J. Gastric Cancer"},{"key":"26388_CR21","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino, A. et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J. Pers. Med. 11, 1095 (2021).","journal-title":"J. Pers. Med."},{"key":"26388_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21037\/jgo-22-462","volume":"13","author":"W Weng","year":"2022","unstructured":"Weng, W. et al. Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer. J. Gastrointest. Oncol. 13, 1035\u20131045 (2022).","journal-title":"J. Gastrointest. Oncol."},{"key":"26388_CR23","first-page":"4","volume":"10","author":"MA Pereira","year":"2021","unstructured":"Pereira, M. A. et al. RhoA, Claudin 18, and c-MET in gastric cancer: Clinicopathological characteristics and prognostic significance in curative resected patients. Med. Sci. (Basel) 10, 4 (2021).","journal-title":"Med. Sci. (Basel)"},{"key":"26388_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4251\/wjgo.v15.i2.343","volume":"15","author":"E Kayikcioglu","year":"2023","unstructured":"Kayikcioglu, E., Yuceer, R. O., Cetin, B., Yuceer, K. & Karahan, N. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma. World J. Gastrointest. Oncol. 15, 343\u2013351 (2023).","journal-title":"World J. Gastrointest. Oncol."},{"key":"26388_CR25","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota, Y. et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 8, 100762 (2023).","journal-title":"ESMO Open."},{"key":"26388_CR26","doi-asserted-by":"publisher","first-page":"20047","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"HD Kim","year":"2023","unstructured":"Kim, H. D. et al. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci. Rep. 13, 20047 (2023).","journal-title":"Sci. Rep."},{"key":"26388_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 23, 283 (2023).","journal-title":"BMC Gastroenterol."},{"key":"26388_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study. Chin. J. Cancer Res. 36, 78\u201389 (2024).","journal-title":"Chin. J. Cancer Res."},{"key":"26388_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00543","volume":"8","author":"R Waters","year":"2024","unstructured":"Waters, R. et al. Retrospective study of Claudin 18 Isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma. JCO Precis. Oncol. 8, e2300543 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"26388_CR30","doi-asserted-by":"publisher","first-page":"oyae238","DOI":"10.1093\/oncolo\/oyae238","volume":"30","author":"Y Kwak","year":"2024","unstructured":"Kwak, Y. et al. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist 30, oyae238 (2024).","journal-title":"Oncologist"},{"key":"26388_CR31","doi-asserted-by":"publisher","first-page":"104000","DOI":"10.1016\/j.esmoop.2024.104000","volume":"9","author":"TY Kim","year":"2024","unstructured":"Kim, T. Y. et al. Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open 9, 104000 (2024).","journal-title":"ESMO Open"},{"key":"26388_CR32","doi-asserted-by":"publisher","first-page":"155628","DOI":"10.1016\/j.prp.2024.155628","volume":"263","author":"M Kim","year":"2024","unstructured":"Kim, M., Kang, B. W., Park, J., Baek, J. H. & Kim, J. G. Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients. Pathol. Res. Pract. 263, 155628 (2024).","journal-title":"Pathol. Res. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26388-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:58:59Z","timestamp":1762516739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26388-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26388"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26388-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6145125\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39072"}}